Changzheng Lu

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 4

Top Topics

Small Cell Lung Cancer

Inflammatory Response

Epithelial Mesenchymal Transition

Tyrosine Kinase

Top Venues

Science translational medicine

Nature communications

Science immunology

Medical review (Berlin, Germany)

This page only lists publications with an associated author ORCID identifier.

Publications

Yaping Huang, Changzheng Lu, Hanzhi Wang, Liya Gu, Yang-Xin Fu, Guo-Min Li
DNAJA2 deficiency activates cGAS-STING pathway via the induction of aberrant mitosis and chromosome instability. Nature communications 14 (1) (2023)
Yitong Cai, Anli Zhang, Changzheng Lu
Precision intervention of cell type-specific targeting is required for future cancer immunotherapy. Medical review (Berlin, Germany) 2 (6) (2023)
Anli Zhang, Zhenhua Ren, Kuo-Fu Tseng, Xiaojuan Liu, Huiyu Li, Changzheng Lu, Yueqi Cai, John D Minna, Yang-Xin Fu
Dual targeting of CTLA-4 and CD47 on Treg cells promotes immunity against solid tumors. Science translational medicine 13 (605) (2021)
Zhida Liu, Chuanhui Han, Chunbo Dong, Aijun Shen, Eric J Hsu, Zhenhua Ren, Changzheng Lu, Longchao Liu, Anli Zhang, Casey Timmerman, Yang Pu, Yang Wang, Mingyi Chen, Jian Qiao, Yang-Xin Fu
Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity. Science immunology 4 (38) (2020)